SCHEMBL166436

SCHEMBL166436

CCOC(=O)c1nc2c(C)csc2c(=O)[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
KDM4E B2RXH2 6/20 0.50
GAA P10253 6/20 0.50
HPGD P15428 5/20 0.50
POLB P06746 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HSD17B10 Q99714 3/20 0.47
TSHR P16473 1/20 0.47
PDE5A O76074 1/20 0.46
TNKS O95271 1/20 0.45
PARP1 P09874 1/20 0.45
TNKS2 Q9H2K2 1/20 0.45
HTT P42858 2/20 0.43
RECQL P46063 1/20 0.43
PDPK1 O15530 1/20 0.42
MAPT P10636 5/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167069 0.78 ALDH1A1 (0.64) ALDH1A1KDM4EGAAHPGDPOLB
SCHEMBL167449 0.76 NPC1 (0.54) ALDH1A1KDM4EGAAHPGDPOLB
SCHEMBL4932760 0.73 ALDH1A1 (0.60) ALDH1A1KDM4EGAAHPGDPOLB
SCHEMBL168128 0.73 ALDH1A1 (0.56) ALDH1A1KDM4EGAAHPGDPOLB
SCHEMBL8201209 0.73 PARP1 (0.56) ALDH1A1KDM4EGAAHPGDPOLB
SCHEMBL8108086 0.73 ALDH1A1 (0.47) ALDH1A1KDM4EGAAHPGDPOLB
SCHEMBL25637210 0.73 PDPK1 (0.54) ALDH1A1KDM4EHPGDCYP1A2CYP2C9
SCHEMBL24261226 0.71 MAPT (0.40) ALDH1A1KDM4EGAACYP1A2CYP2C19
SCHEMBL164692 0.71 MAPT (0.40) ALDH1A1GAAPOLBCYP1A2CYP2C19
SCHEMBL13343477 0.71 ALDH1A1 (0.51) ALDH1A1KDM4EGAAHPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130317045-A1 THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-11-28 US disclosed
EP-2611812-A1 THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-07-10 EP disclosed
WO-2012030894-A1 THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130317045-A1 THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF JAK2, JAK3, TYK2 ALDH1A1 2385/4885KDM4E 1605/4885GAA 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.